The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.
CARL. Resuscitec awarded with the Lothar Späth Award 2023
Yesterday, Thursday evening, November 16, 2023, Resuscitec, represented by our management Prof. Benk, Mr. Ronde and Dr. Kraft, together with our cooperation partner from the Medical Center – University of Freiburg, represented by Prof. Beyersdorf, received the 1st prize of the Lothar Späth Award 2023 in the Zeiss Planetarium Jena.
The recognition includes research achievements, technological translation into innovative products and services as well as the entrepreneurial achievement of successful market entry.
Background: The Lothar Späth Award was presented for the first time in 2018 and underlines the spirit of the namesake’s work and thinking. In particular, knowledge transfer and the promotion of cooperation between research and industry should be recognized and strengthened in Baden-Württemberg and Thuringia. All applications go through a highly qualified screening committee, including the Karlsruhe Institute of Technology (KIT) and selected experts, before a top-class jury from politics, business and science determines the final prize winners according to defined criteria.
This award is a special recognition for all employees and “CARL friends” who have traveled our path together to this day. At the same time, it also raises the bar to continuously work on patient access to CARL Therapy as well as improve neurological-intact patient survival after refractory cardiac arrest.